Login to Your Account



EASL Roundup


Monday, April 4, 2011
Merck & Co. Inc., of Whitehouse Station, N.J., reported final results from a Phase III study of Victrelis (boceprevir), its oral protease inhibitor for hepatitis C virus (HCV), in combination with standard of care (SOC) peginterferon alfa-2a and ribavirin, with data showing that, over the 48-week treatment period, two-thirds (64 percent) of treatment-failed patients with HCV genotype 1 receiving the triple-drug therapy achieved sustained virologic response (SVR) vs. 21 percent receiving SOC alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription